Elite Pharmaceuticals Inc (ELTP)

[freegriff]

Serious question. I was reading over EGLT, a competitor who has an upcoming IR ADT PDUFA.

As you all might recall, theire ER ADT only got a single ADT label, not the trifecta. I read the following "The good news: the company received approval in Jan. 2017 and will be selling ARYMO ER in 2Q17; the unexpected bad news: the FDA permitted the label to state that ARYMO was an AD product by the intravenous route of abuse, but not oral or nasal routes of abuse, because a competing product (MorphaBond by privately-held Inspirion Delivery Sciences) was granted a three-year label exclusivity for the other routes of abuse when it was approved in October 2015." from Bret Jensen.

The question is, are we in danger, if SequestOX does not reach labeling first, at missing out on the labeling if we are not first?